Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells

Abstract

Cladribine (2CdA), a synthetic purine analog interfering with DNA synthesis, is a medication used to treat hairy cell leukemia (HCL) and B-cell chronic lymphocytic leukemia. Entinostat, a selective class I histone deacetylase (HDAC) inhibitor, shows antitumor activity in various human cancers, including hematological malignancies. The therapeutic potential of cladribine and entinostat against multiple myeloma (MM) remains unclear. Here we investigate the combinatorial effects of cladribine and entinostat within the range of their clinical achievable concentrations on MM cells. While either agent alone inhibited MM cell proliferation in a dose-dependent manner, their combinations synergistically induced anti-proliferative/anti-survival effects on all MM cell lines (RPMI8226, U266, and MM1.R) tested. Further studies showed that the combinations of cladribine and entinostat as compared to either agent alone more potently induced mitotic catastrophe in the MM cells, and resulted in a marked increase of the cells at G1 phase associated with decrease of Cyclin D1 and E2F-1 expression and upregulation of p21waf−1. Apoptotic ELISA and western blot analyses revealed that the combinations of cladribine and entinostat exerted a much more profound activity to induce apoptosis and DNA damage response, evidenced by enhanced phosphorylation of histone H2A.X and the DNA repair enzymes Chk1 and Chk2. Collectively, our data demonstrate that the combinations of cladribine and entinostat exhibit potent activity to induce anti-proliferative/anti-survival effects on MM cells via induction of cell cycle G1 arrest, apoptosis, and DNA damage response. Regimens consisting of cladribine and/or entinostat may offer a new treatment option for patients with MM. Abbreviations: MM, multiple myeloma; HCL, hairy cell leukemia; HDAC, histone deacetylase; Ab, antibody; mAb, monoclonal Ab; FBS, fetal bovine serum; CI, combination index; PAGE, polyacrylamide gel electrophoresis; ELISA, enzyme-linked immunosorbent assay; PARP, poly(ADP-ribose) polymerase; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,inner salt

Autophagy Inhibition Potentiates the Anticancer Effects of a Bendamustine Derivative NL-101 in Acute T Lymphocytic Leukemia

“…us, a novel strategy on the treatment of T-ALL is urgently required. HDACi vorinostat is used to treat cutaneous T-cell lymphoma (CTCL), while another HDACi panobinostat was used for multiple myeloma [26]. In contrast to high cytotoxic response in vitro, the effect in vivo is not ideal.…”

Antileukemic activity of novel adenosine derivatives

“…Nucleoside analogs inhibit ribonucleotide reductase and reduce the amount of deoxynucleotides in the cell. Cladribine modifies level of histones, inhibits the action of anti-apoptotic proteins, reduces the mitochondrial membrane potential, increases the production of reactive oxygen species in cells and causes intracellular calcium growth, resulting in the release of apoptosis-inducing factors such as cytochrome C, second mitochondria-derived activator of caspases/direct IAP-binding protein with low PI, and apoptosis-inducing factor 4,7,8 . Cladribine also promotes arrest of the cell cycle in the G 2 /M phase, condensation of chromosomes and DNA fragmentation.…”

Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty

“…Using immunomodulating or immunosuppressive drugs is unfortunately accompanied by high risk of cancer development due to involvement of immune system in recognizing and eliminating cancer cells [182]. On the other hand, some available MS DMTs have been used for years in cancer therapy (e.g., rituximab [184], cladribine [185] and methotrexate [186]), while other current DMTs are being evaluated in the present for their anti-tumor potential (e.g., dimethylfumarate [187], fingolimod [188] and teriflunomide [189]).…”